Chris Liang is the founder of HighlightLL Pharma. HighlightLL Pharma has raised $38M in total funding. Latest round: Series B. Based in Hangzhou, China.
Chris Liang is a co-founder and CEO of HighlightLL Pharma, a company developing a TYK2/JAK1 inhibitor for autoimmune and inflammatory diseases. The company has raised over RMB210 million ($30 million) across its Series B and B+ rounds. Liang previously co-founded Xcovery Holding Co. LLC, where he discovered and led the development of two drugs, ensartinib and vorolanib, and was the principal inventor of the cancer drug Sutent.
Full founder directory · Investor directory · Company funding database · Fundraising library